GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2007

Pfizer Taps Medivas to Provide Delivery Methods for its Ophthalmic Compounds

  • MediVas and Pfizer will collaborate on R&D related to delivery methods for Pfizer compounds to treat eye diseases. By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, the companies hope to create a product that can change the paradigm of how ophthalmic treatments are administered.

    "We are confident that by combining Pfizer's compounds with our polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye,” remarks Kenneth W. Carpenter, MediVas' president and CEO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Cancer Drug Approvals and Efficacy

Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?

More »